(Reuters) – FibroGen Inc said on Friday its anemia drug had failed to meet the main goal in a late-stage trial, sending its shares tumbling nearly 13% before the bell.
The drug, roxadustat, was being studied for the treatment of anemia in patients with a type of bone marrow cancer.
(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)
